Key Highlights
- $52.5M Series C funding co-led by B Capital and U.S. Venture Partners.
- Funds designated for accelerating aprevo® lumbar fusion procedures and development for cervical fusions.
- Carlsmed’s FDA Breakthrough Device designation for lumbar and cervical patient-specific interbody fusion devices.
Source: Business Wire
Notable Quotes
- “We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo® patient-specific implants are achieving this goal,” – Mike Cordonnier, CEO at Carlsmed
- “Carlsmed is transforming spine surgery through the application of its AI-enabled technology and has proven to be a category creator in a market overdue for meaningful innovation,” – Dr. Robert Mittendorff, General Partner and Head of Healthcare at B Capital
SoHC's Take
Carlsmed’s recent funding round marks a significant milestone in the advancement of personalized surgery. The investment reflects a strong confidence in Carlsmed’s innovative approach and its potential to set new standards in healthcare outcomes. The emphasis on accelerating the commercialization of the aprevo® platform for lumbar fusion procedures and expanding its application to cervical fusions highlights the company’s commitment to advancing spine surgery. With the FDA’s Breakthrough Device designation, Carlsmed is well-positioned to lead the transformation in spine surgery, offering more personalized and effective treatment options for patients. This development is not just a win for Carlsmed but signals a promising direction for the entire Medtech industry, moving towards more customized and patient-specific healthcare solutions.
